Lintuzumab actinium ac-225
As of the edition of 20 October 2026, Lintuzumab actinium ac-225 is an antibody: stopped in 2020; acts on CD33.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2020
- Kind
- Antibody
- Registered trials
- 5, 2 stopped early
- Disease areas
- Blood and lymph; Cancer; Heart and blood vessels; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Lintuzumab actinium ac-225.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CD33 | Myeloid cell surface antigen CD33 | P20138 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 4 | 2 | 0 | 2 |
| Phase 2 | 1 | 1 | 0 | 0 |
| All trials | 5 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Actinium Pharmaceuticals | Lead sponsor of trials | 2012 to now |